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PainThe expression and function of TRPV1 are inﬂuenced by its interaction with cellular proteins. Here, we identify
Whirlin, a cytoskeletal PDZ-scaffold protein implicated in hearing, vision and mechanosensory transduction, as
an interacting partner of TRPV1. Whirlin associates with TRPV1 in cell lines and in primary cultures of rat
nociceptors. Whirlin is expressed in 55% of mouse sensory C-ﬁbers, including peptidergic and non-peptidergic
nociceptors, and co-localizes with TRPV1 in 70% of them. Heterologous expression of Whirlin increased TRPV1
protein expression and trafﬁcking to the plasmamembrane, and promoted receptor clustering. SilencingWhirlin
expressionwith siRNA or blocking protein translation resulted in a concomitant degradation of TRPV1 that could
be prevented by inhibiting the proteasome. The degradation kinetics of TRPV1 upon arresting protein translation
mirrored that ofWhirlin in cells co-expressing both proteins, suggesting a parallel degradation mechanism.
Noteworthy, Whirlin expression signiﬁcantly reduced TRPV1 degradation induced by prolonged exposure
to capsaicin. Thus, our ﬁndings indicate that Whirlin and TRPV1 are associated in a subset of nociceptors
and that TRPV1 protein stability is increased through the interaction with the cytoskeletal scaffold protein.
Our results suggest that the Whirlin–TRPV1 complex may represent a novel molecular target and its phar-
macological disruption might be a therapeutic strategy for the treatment of peripheral TRPV1-mediated
disorders.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Transient receptor potential vanilloid 1 (TRPV1) is a thermosensory
channel activated by physical and chemical stimuli (1). This ion channel
was initially described as the sensor for noxious temperatures (N42 °C)
and vanilloid molecules such as capsaicin (2). TRPV1 is also gated by
very strong membrane depolarization, and its gating mechanism can
be potentiated by mild extracellular acidiﬁcation (3,4). A hallmark of
TRPV1 activity is its signiﬁcant potentiation by pro-algesic agents re-
leased upon tissue injury or inﬂammation (5). This potentiation is pro-
duced by alteration of the channel gating mechanism by chemical
modiﬁcation of the protein (6), and/or by enhancing the recruitment
of new channels to the plasmamembrane through regulated exocytosis
of receptors stored in large-dense core vesicles (7). The pivotal role
in the onset, setting and maintenance of nociceptor inﬂammatory
sensitization has signaled TRPV1 as a valuable therapeutic target for
pain intervention (8), leading to the implementation of a plethora ofR. Planells-Cases),drug discovery programs that have provided amyriad of channel antag-
onists (9). However, none of these molecules has been developed clin-
ically yet because of unwanted side effects arising from extensive
blockade of the receptor (10).
Structurally, TRPV1 is a homomeric integral membrane protein
displaying the assembly of four identical subunits around a central
axis of symmetry centered in the channel pore (11). Each subunit con-
tains 6-transmembrane segments, of which S5 and S6 structure the
walls of the permeation pathway, while the other segments contribute
to the design of part of the gating sensors (12). In addition, each subunit
contains a cytosolic C-terminal domain that has been involved in regu-
lating the association of subunits and channel gating (13,14). Further-
more, the N-terminus is also a cytosolic domain that displays the
presence of several ankyrin domains, which mediate the interaction
with cellular proteins thus contributing to deﬁne the activity of the
thermosensory channel, either by modulating its gating properties
(15), or its trafﬁcking, insertion and clustering into the plasma mem-
brane (16).
Noteworthy, it is becoming clear that ion channels are not isolated
molecular devices but rather components of protein complexes, that
through orchestrated interactions contribute to deﬁne their signaling
in a time- and context-dependent manner (17). Thus, elucidating the
Table 1
TRPV1 coexpresses with Whirlin isoforms in sensory neurons.
WT Whirlinneo/neo Whirler
TRPV1+ 33 ± 1 31 ± 1 34 ± 1
TRPV1+ x IB4+ 4 ± 1 6 ± 1 4 ± 1
TRPV1+ x CGRP+ 50 ± 4 49 ± 3 40 ± 4
TRPV1+ x NF200+ 11 ± 1 11 ± 2 11 ± 3
TRPV1+ x Whirlin+ 64 ± 2 63 ± 4 61 ± 3
Whirlin+ 56 ± 1 51 ± 2 53 ± 1
Whirlin+ x IB4+ 37 ± 2 35 ± 3 43 ± 5
Whirlin+ x CGRP+ 54 ± 2 49 ± 6 53 ± 5
Whirlin+ x NF200+ 41 ± 3 42 ± 4 31 ± 5
Whirlin+ x TRPV1 + 40 ± 2 40 ± 3 41 ± 4
Immunohistochemistry was carried out on serial DRG cryo-sections of 14 μm from wild
type, whirler and Whirlinneo/neo mice. Immunohistochemical staining was performed
with polyclonal antibodies for TRPV1, Whirlin and the neuronal markers CGRP, IB4 and
NF200. Data expressed mean ± SEM as percentage of total neurons analyzed per section.
Three animals and a minimum of 5 sections per group were analyzed.
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understand the contribution of this thermoTRP to thermal sensation as
well as to nociceptor sensitization under pathological conditions. To
identify interacting TRPV1 proteins, we used the yeast two-hybrid
approach to screen a cDNA neuronal library using the N-terminus
domain of TRPV1 (NtTRPV1) as bait. Our screening identiﬁed the cy-
toskeletal PDZ-scaffold protein Whirlin, also known as calmodulin-
dependent serine kinase (CASK)-interacting protein of 98 kDa
(CIP98) (18), as a putative TRPV1 interacting partner. Whirlin has
three Class I PDZ domains (19), two located in the N-terminus and
a Proline-rich region at the C-terminus, between the second and
third PDZ domains (20). Whirlin was initially identiﬁed as a protein
that interacts with CASK, a member of the membrane-associated
guanylate kinase (MAGUK) that plays an important role in synaptic
development and plasticity (21). Notably, in humans Whirlin is
encoded by the Deafness Autosomal Recessive 31 (DFNB31) locus.
Genetic defects in the Whirlin gene cause non-syndromic deafness
and the Usher2 syndrome (22,23). Recently, a role in mechanosensory
signaling has also been uncovered for Whirlin consistent with its ex-
pression in mammalian proprioceptors (24). Collectively, all these
data imply a central role of Whirlin in hearing, vision and sensory
transduction.
Here, we show that Whirlin interacts with TRPV1 in transfected cell
lines and in DRG neurons. Noteworthy, TRPV1 associates with long and
short isoforms of Whirlin. Heterologous co-expression of Whirlin with
TRPV1 increases the total and membrane expression of the vanilloid
receptor. This enhanced channel expression is not translated into
higher channel function because of receptor clustering in the cell
membrane. Conversely, silencing of Whirlin expression using
speciﬁc siRNA decreased the level of TRPV1 cellular expression and
reduced channel activity. This effect was prevented by inhibition of
the proteasome that inhibits Whirlin and TRPV1 degradation. Note-
worthy, in cells co-expressing TRPV1 and Whirlin the kinetics of
TRPV1 proteasomal degradation paralleled that of Whirlin, and the
PDZ-scaffold protein reduced TRPV1 internalization and degrada-
tion due to prolonged exposure to capsaicin. Taken together, our
ﬁndings indicate that Whirlin complexes with TRPV1 and stabilizes
its cellular and membrane expression.
2. Materials and methods
2.1. Chemicals and antibodies
All drugs were from Sigma (St. Louis, MO, USA) unless otherwise
stated. Anti-Whirlin serum (Genscript Corporation), polyclonal anti-
Whirlin (Abcam), anti-TRPV1 serum (16), polyclonal anti-TRPV1
(Alomone Labs Ltd., Chemicon), anti-TRPV1 extracellular (α-TRPV1e)
(7), rabbit anti-neuroﬁlament 200, Isolectin B4-Alexa 568 (MolecularProbes) and goat anti-CGRP (Abcam) were used. Secondary antibodies
were from Jackson ImmunoResearch Laboratories.2.2. Yeast two-hybrid screen
The yeast 2-hybrid screen was performed with the cytosolic N-
terminal domain of TRPV1 (NtTRPV1), as previously described (16).2.3. Plasmids and deletions
Human Whirlin cDNA (Open Biosystems) was subcloned in
pcDNA3.1-Myc-His plasmid (Invitrogen) for eukaryotic expression.
The cytosolic NtTRPV1 domain was cloned in pGEX-4T-1 vector (GE
Healthcare) to be expressed as a GST-fusion protein. The truncated
formTRPV1-VStopwas obtained by introducing a stop codon at position
Val-828. The HA-TRPV1 and YFP-TRPV1 usedwere described previously
(13,25).2.4. Animal models
All experimental procedures were approved by the Institutional
Animal and Ethical Committee of the University Miguel Hernández
de Elche and in accordance with the guidelines of the Economic
European Community. Neonatal Wistar rats and wild-type C57BL/6J
mice were in house-bred from a stock originally from Harlan Laborato-
ries.Whirlermicewere kindly provided byDr. P.Mburu (20). Genetical-
ly, the mutation in the Whirler mice consists of a 592 bp deletion that
leads to a truncation of the long isoform before the third PDZ and en-
compasses the ﬁrst methionine of the short isoform. Whirlinneo/neo
mice are transgenic mice that do not express the long isoform of the
PDZ protein, and were obtained as described (26).2.5. Genotyping
Genomic DNAwas extracted frommice tails. Forwhirlermice, prim-
er sequences and cycling conditions for PCR were obtained from Dr.
Mburu's lab as follows: TGGCCAACCTCTGTGCTTCC (D4Mit17) and
ACAGTTGTCCTCTGACATCC (D4Mit17 rev), resulting in 110-bp band
for wild type and CAAAATATCTGACAAAAACAAGTGTG (D4Mit244)
and GGTGTCATCACCATGATGGA (D4Mit244 rev), resulting in 110-bp
band for wild type and a 130 band for Whirler. Cycling conditions
used were 94 °C for 3′, 35 cycles, 94 °C for 2′, 58 °C for 1′, and 68 °C
for 2′. ForWhirlinneo/neo mice, primer sequences and cycling conditions
were as described (27).2.6. Cell culture
Primary cultures of neonatal rat or adult mice DRG neurons were
prepared as in (7,28) respectively. Human embryonic kidney cells
(HEK293) and a hybridoma of the mouse neuroblastoma cell line
N18TG-2 andembryonic ratDRGs (F11 cells)were cultured as previous-
ly described (29,30) and used 48 h after transfection with JetPeI™
(Polysciences) or Lipofectamine™ (Invitrogen) following the
manufacturer's instructions.
For DRG electroporation, the Neon transfection system (Invitrogen)
was used following the manufacturer's instructions. Neurons were
extracted from neonatal rats and after digestion with collagenase,
they were resuspended in 10 μl of resuspension buffer plus 1 μg
cDNA per reaction (Whirlin or YFP as control). Two pulses of 20 ms
at 1200 V were applied and cells then resuspended and seeded in
complete medium without antibiotics for 3–4 h before changing to
complete medium.
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Three different siRNAs (Ambion) were used to suppress Whirlin
expression in F11 and DRG cultures: C1 (CGAUAAAUCUCUAGCCCGG,
chromosome 5–587 in exon 1), C2 (GGAUUUACAAGGGCCCAG,
chromosome 5–1212 in exon 6), and C3 (CCAUGAUGUACUACCU
AGA, chromosome 5–1327 in exon 6). A scrambled siRNA (a
siRNA with a random sequence) was also used as negative control.
As the three siRNAs recognized species-speciﬁc sequences from the
Rattus norvegicus ortholog of Whirlin (NCBI reference sequence:
NM_181088), this was isolated by PCR from a rat brain cDNA library
(16), and subsequently subcloned in the pcDNA 3.1-Myc-His plasmid.
The resulting plasmid was cotransfected with TRPV1 in F11 cells in the
presence of either of the siRNAs as described above.
2.8. Quantitative real time PCR
Total RNA was isolated from rat DRGs using E.Z.N.A.™ HP Total RNA
Kit (Omega). RNA concentration was estimated and 1 μg RNAwas used
for reverse transcription with Gene Amp® RNA PCR (Applied
Biosystems), according to the manufacturer's conditions. Quantitative
real time PCR (qPCR) was performed with 20 ng cDNA using appropri-
ate TaqMan® for ratWhirlin (reference number 00710383_m1, Applied
Biosystems) and TaqMan PCR Mastermix (Applied Biosystems). Three
replicates for each sample were tested. Singleplex reactions were run
with an ABI PRISM 7700 thermocycler (Applied Biosystems) using the
following cycling conditions: 50 °C for 2 min; 95 °C for 10 min; and 40
cycles (95 °C for 15 s; 60 °C for 1 min). A non-template sample was
used as a control.
2.9. In vitro pull-down assay
GST fusion proteins were in-batch afﬁnity puriﬁed on
glutathione-Sepharose 4B (GE Healthcare). HEK293 cells were
transfected with myc-tagged Whirlin (Whirlin-myc) cDNA and cul-
tured for 48 h. Immobilized GST-NtTRPV1 domain or GST as control
were incubated overnight at 4 °C with HEK293 myc-tagged Whirlin
extracts in buffer (containing in mM: 100 NaCl; 10 MgCl2; 10 Tris; 5
EDTA, pH 7.5; 1% Triton X-100 and 0.5% NP-40). After several
washes with the same buffer, protein complexes were eluted, dena-
tured, and resolved by SDS/PAGE.
2.10. Co-immunoprecipitation
HEK293 cells co-transfected with the TRPV1 wild type or VStop and
Whirlin-myc or PSD95-myc were solubilized in RIPA buffer (50 mM
Tris–Cl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) containing protease inhibitors. The solubilized supernatants
(~900 μg of protein) were incubated overnight at 4 °C with 10 μl of
anti-c-Myc agarose (Pierce). Immunocomplexes were washed three
timeswith a solution of TBS plus 0.05% Tween-20, elutedwith SDS sam-
ple buffer and analyzed by immunoblotting.
2.11. Biotin labeling of surface proteins
HEK293 cells transiently coexpressing TRPV1 plus Whirlin-myc (or
plus YFP in control) were incubated with 0.5 mg/ml sulfo-NHS-SS-
Biotin (Pierce) for 30 min at 4 °C. Plates were rinsed with Tris 10 mM
pH 7.4, 150 mM NaCl and incubated in the same buffer for 30 min at
4 °C to quench unreacted biotin. Cells were lysed for 1 h at 4 °C with
lysis buffer (50 mMHEPES pH 7.4; 140 mM NaCl; 10% glycerol; 1% Tri-
ton X-100; 1 mM EDTA; 2 mM EGTA; 0.5% deoxycholate) containing
protease inhibitors. Biotin-labeled proteins were isolated incubating
cell lysateswith streptavidin agarose overnight at 4 °C. Isolated fractions
were resolved by SDS-PAGE.2.12. Immunocytochemistry
Primary DRG cultureswere ﬁxed, blocked, permeabilized and subse-
quently incubated with both guinea pig anti-capsaicin receptor anti-
body (Chemicon) and anti-Whirlin serum (Genscript) or polyclonal
antibody (Abcam). HEK293 cells were co-transfected with TRPV1 plus
Whirlin-myc (or plus DsRed in control) and cultured 48 h before
incubation 1 h at 4 °C with rabbit anti-rat TRPV1 extracellular
(Alomone Labs Ltd.), a TRPV1 antibody that speciﬁcally recognizes
an extracellular epitope (7). After several washes, cells were ﬁxed,
permeabilized and thereafter incubated overnight at 4 °C with
mouse anti-c-myc. After extensive washing cells were incubated
with the secondary antibodies, mounted and analyzed by confocal
microscopy (Leica TCS).
2.13. Immnohistochemistry
Mice were over-anesthetized with pentobarbital (50 mg/kg, i.p. in
saline) and then transcardially perfused through the left ventricle with
cold saline followed by 4% PFA in PBS (pH 7.4). Isolated DRGs were
post-ﬁxed for 4 h in the same ﬁxative solution at 4 °C, immersed in su-
crose gradient solutions (10, 20, and 30%) in PBS for cryoprotection until
the tissues sunk and then frozen with dry ice in mounting medium
(O.C.T.™, Tissue-Tek). DRGs were serially cut at 14 μm thickness on a
cryostat, mounted onto polylysine-coated Menzel-Gläser Superfrost
UltraPlus® slides (Thermos Scientiﬁc), and kept at −20 °C until use.
Slides were then defrosted, washed, blocked/permeabilized with 10%
normal goat or donkey serum, 3% BSA and 0.3% Triton X-100 in PBS
and incubated o/n at 4 °C with the primary antibodies diluted in the
blocking solution. After washing with PBS–Tween 0.05%, sections were
incubated with the appropriate secondary antibodies (1 h at RT) and
mounted with Mowiol® (Calbiochem). Cell nuclei were stained with
DAPI (300 nM in PBS, 5min, RT) (Molecular Probes, Invitrogen). Sample
images were captured with an inverted confocal microscope (Zeiss LSM
5Pascal, Carl Zeiss, 40× objective) and then analyzedwith Zen Lite 2012
software (Zeiss) under blinded conditions to determine the percentage
of TRPV1 or Whirlin positive neurons that were also positive for CGRP,
IB4 or NF200 markers (referred to as TRPV1+ x marker+ or Whirlin+
x marker+). More than ﬁve sections per animal, three mice, and
N1000 total neurons per group were analyzed. Data were expressed as
means ± SEM and statistical analysis was performed by two-way
ANOVA, followed by Bonferroni post-test. Signiﬁcance level was preset
to p b 0.05.
2.14. Ca2+ imaging
HEK293 cells cotransfected with TRPV1 andWhirlin-myc, or pcDNA
in control, were loaded with 5 μM ﬂuo-4-acetoxymethyl ester (Fluo-4-
AM, Molecular Probes) in the presence of 0.02% pluronic F-127 acid
(Invitrogen) in Hank's balanced salt solution (HBSS) (140 mM NaCl,
4 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM D-glucose, 10 mM
HEPES pH 7.4) for 1 h at 37 °C in darkness. Coverslips were then
mounted in an imaging chamber continuously perfused (1 ml/min)
withHBSS at ~22 °C using amultibarreled gravity-driven, automatic op-
erated perfusion system.
TRPV1 activity was evoked with a ﬁrst 15-s pulse of capsaicin
0.01, 0.1, 1 and 10 μM and a second 15 s pulse of a supramaximal
concentration of capsaicin (100 μM) after a 5-min washing with
HBSS. The same protocol was applied for DRG cultures plus an
additional brief (15 s) application of 40 mM KCl to distinguish neu-
rons from non-neuronal cells and to ensure that cells were healthy
and responsive. Fluorescence from individual cells was monitored
as a function of time and measured with a Zeiss Axiovert 200
inverted microscope (Carl Zeiss) ﬁtted with an ORCA-ER CCD
camera (Hamamatsu Photonics) through a 10× or 20× air objec-
tive. Fluo-4 was excited at 500 nm using a computer-controlled
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rescence was ﬁltered with a 535-nm long-pass ﬁlter. Images were
acquired and processed with AquaCosmos package software(Hamamatsu Photonics). The amplitude of Ca2+ increase caused
by stimulation with capsaicin was measured by subtracting the
basal ﬂuorescence (before capsaicin application) to the peak of
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expressed as means ± SEM, with n = number of cells tested and
N=number of experiments realized. Statistical analysiswas performed
by two-way ANOVA, followed by Bonferroni post-test and signiﬁcance
level was preset to p b 0.05.
2.15. Calcium microﬂuorographic assay
F11 cells were seeded in black 96 well plate with clear ﬂat bottom
and transfected with rat TRPV1 and Whirlin cDNAs and/or previously
described siRNA. After 48 h cellswere incubatedwith 100 μl of dye load-
ing solution (1× HBSS, 20 mM HEPES, pH 7.4), containing the ﬂuores-
cence calcium indicator Fluo4-NW (Molecular Probes) and 2.5 mM
probenecid, for 45 min at 37 °C and 10 min at room temperature.
Through the microplate reader POLARstar Omega (BMG Labtech) the
Fluo-4 ﬂuorescence signal (excitation at 494 nm and emission at
516 nm) was measured during 18 cycles. TRPV1 activity was evoked
by the addition of 100 μM capsaicin in the ﬁfth cycle using the injection
system of the plate reader. We quantiﬁed the response to capsaicin by
calculating the area under the curve (AUC) between the ﬁfth and the
eighteenth cycles, generated by the increase of ﬂuorescence signal in-
duced by the response to capsaicin.
2.16. Electrophysiology
HEK293 cells were cotransfected with a mixture of TRPV1, Whirlin-
myc, and CD8 (as a reporter) cDNAs, in a 2:2:1 ratio, and cultured for
48 h before being tested. In control samples, Whirlin was replaced by
YFP. For selection, cells were incubated with 1 μl of anti-CD8-coated
magnetic beads (Dynal). Patch pipettes (1.5 mm external and 1 mm in-
ternal diameter) were prepared from thin-borosilicate glass (World
Precision Instruments) with a P-97 horizontal puller (Sutter Instru-
ments) and ﬁre-polished with a microforge MF-830 (Narishige) to
have a ﬁnal resistance of 2–3 MΩ. Standard whole-cell voltage-clamp
protocols were applied using an EPC-10 ampliﬁer (HEKA Electronic). Pi-
pettes were ﬁlled with standard internal solution containing (in mM):
144 KCl, 2 MgCl2, 5 EGTA and 10 HEPES. The pH was adjusted to 7.2
with KOH and the osmolarity set to 295 mosmol/kg. Standard extracel-
lular solution contained (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10
HEPES, 5 glucose and 20 mannitol. The pH was adjusted to 7.4 and the
osmolarity set to 320mosmol/kg. For acid solution, HEPESwas replaced
with MES and pH adjusted to 6. The different saline solutions were ap-
plied with a gravity-driven local microperfusion system with a rate
ﬂow of about 500 μl/min located within about 300 μm of cell under
study. Capsaicin stock (100 mM) was prepared in DMSO and diluted
as indicated for the experiments in bath solution the day of the experi-
ment. All recordings were performed at room temperature (22–24 °C).
Voltage-step protocols consisting of 100 ms depolarizing pulses
from−120 mV to +220 mV in steps of 20 mV were used. The holding
potential (Vh) was−60 mV and the time interval between each pulse
was 5 s. The conductance–voltage (G–V) curves were obtained by
converting the maximal current values from the voltage step protocol
to conductance using the relation G = I / (V− VR), were G is the con-
ductance, I is the peak current, V is the command pulse potential, and
VR is the reversal potential of the ionic current. G–V curves for each
cell were ﬁtted to the Boltzmann equation: G = Gmax / 1 + exp
[zg(V− V0.5) / kT], where Gmax is the maximal conductance, V0.5 is the
voltage required to activate the half-maximal conductance, and zg isFig. 1. TRPV1 associates in vitro and ex vivo with Whirlin. (A) Pulldown assay using immobiliz
ciated a recombinant full-lengthWhirlin-myc produced in HEK293 cells. GSTwas used as a con
(deletion 828–838 amino acids at the C-terminus or TRPV1) withWhirlin-myc or PSD95-myc p
Whirlin-myc, PDZ1 + 2-myc and PDZ3-myc truncated forms of Whirlin in HEK293 cells. (D, E)
natal rat (D) or adult mice (E) nociceptors by immunoﬂuorescence. Left panel: TRPV1 labele
Whirlin antibody directed against a C-terminal epitope for rat and mouse DRGs, respectively (
squared regions are zoomed at the right side. Scale bar 10 μm.the gating valence. Thereafter, estimated Gmax values were used to ob-
tain the normalized G/Gmax− V curves.
Capsaicin- or acidic pH-evoked currents were elicited with Vh set at
−60 mV. Pulses were applied for a time sufﬁcient for the response to
reach plateau. Current density was calculated by dividing the whole-
cell current by the cell capacitance. Data were visualized and analyzed
using PulseFit (HEKA Electronic), GraphPad Prism 5 statistical software
(GraphPad Software) and Origin 8.0 (OriginLab Corporation). All data
were expressed as means ± SEM, with n = number of cells tested. For
statistical analysis, the unpaired t test was applied and signiﬁcance
level was preset to p b 0.05.3. Results
3.1. Whirlin interacts with TRPV1
A yeast two-hybrid screen, using the cytosolic N-end domain of
TRPV1 as bait (16), identiﬁed, among others, the cytoskeletal Whirlin/
CIP98/DFNB31 as a potential TRPV1 interacting protein. Whirlin is a
PDZ-scaffold protein that plays a pivotal functional role in retinal photo-
receptors and in vestibular and cochlear hair cells (20,26,31), as well as
it contributes to mechanosensory transduction in proprioceptors (24).
The interaction of both proteins was conﬁrmed in vitro with pull-
down experiments using bacterially expressed GST-NtTRPV1. This re-
combinant protein pulled down Whirlin-myc from a HEK293 extract
expressing the PDZ-scaffold protein (Fig. 1A), suggesting an interaction
of TRPV1 ankyrin domains and theWhirlin PDZ domains.We next eval-
uated whether Whirlin-myc interacted with TRPV1 full-length in cells
using a co-immunopuriﬁcation strategy. As illustrated in Fig. 1B, an
anti-myc monoclonal antibody co-immunoprecipitated Whirlin-myc
and TRPV1 from a whole HEK293 cell extract containing both proteins.
Similarly, we could immunoprecipitate Whirlin-myc using a polyclonal
anti-HA antibody to immunoprecipitate HA-TRPV1 (Supplemental in-
formation, Fig. S1), corroborating that both proteins complex when
co-expressed in cells. Furthermore, TRPV1 was also able to associate
with PSD95 another protein having PDZ domains (Fig. 1B). We identi-
ﬁed a potential PDZ internal ligand in the C-end of TRPV1 (SMV at
amino acids 832 to 834), but found that deletion of this sequence did
not affect Whirlin binding to TRPV1 (Fig. 1B, V-stop line). Collectively,
these results indicate a putative, non-canonical interaction of TRPV1
N-terminus, presumably by the ankyrin repeats and PDZ domains.
Structurally, Whirlin displays two PDZ domains at the N-terminus, a
third one at the C-end, and a Proline-rich region between the second
and third PDZ domains (20). Thus, we questioned which of the PDZ
domains mediated the interaction with TRPV1. To address this question,
we truncatedWhirlin in two segments, one encompassing the PDZ1 and
PDZ2 domains (PDZ1 + 2-myc), and the other containing the Pro-
rich region and the PDZ3 (PDZ3-myc). These truncations were co-
expressed with TRPV1 in HEK293 cells for co-immunopuriﬁcation
assays. Notably, both truncated proteins were able to strongly bind
and immunopurify TRPV1 (Fig. 1C), indicating that the interaction
of Whirlin with the thermoTRP can be sustained by the three PDZ do-
mains. This result is relevant since Whirlin is expressed as long and
short isoforms resulting from splicing (32). Taken together, these results
indicate that TRPV1 and Whirlin can form a stable complex in cells that
implies an interaction of TRPV1 N-terminus and Whirlin PDZ domains.
To investigate the physiological relevance of TRPV1–Whirlin associ-
ation, we determined whether both proteins co-localize in sensoryed fusion protein between GST and the cytosolic TRPV1 Nt-domain (GST-Nt-TRPV1) asso-
trol. (B) Co-immunoprecipitation of transiently expressed TRPV1 full length, TRPV1 V-Stop
roteins in HEK293 cells. (C) Co-immunoprecipitation of transiently expressed TRPV1with
Co-localization of endogenous TRPV1 andWhirlin expression in primary cultures of neo-
d with anti-TRPV1 antibody (raised against an intracellular epitope; red). Middle panel:
green). Right panel: overlay of TRPV1 and Whirlin immunoreactivities (yellow). Depicted
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For this purpose, we used qPCR to amplify Whirlin mRNA and western
immunoblots to detect protein expression. Both techniques readily
detected the presence ofWhirlin in primary cultures of rat sensory neu-
rons (Supplemental information, Fig. S2). Second, we used immunocy-
tochemistry to evaluate if Whirlin and TRPV1 co-express in the sameneurons. As depicted in Fig. 1D and E, both proteins were present in
nociceptors from neonatal rat and adult mouse DRGs (Supplementary
information, Fig. S3). In primary cultures of nociceptors, Whirlin and
TRPV1 displayed a cortical co-localization in the neuronal soma (Fig.
1D and E). Third, we employed immunohistochemistry to investigate
the presence of both proteins in DRG cryo-sections (Supplementary
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in 55% of peripheral ﬁbers, including C-type (peptidergic and non-
peptidergic sensory neurons) andA-typeﬁbers (Table 1), substantiating
the presence ofWhirlin in peripheral sensory neurons (24). Around 70%
of theWhirlin positive ﬁbers also expressed TRPV1 (Table 1). Therefore,
these observations imply that Whirlin and TRPV1 are present in DRG
neurons and appear to be part of a protein complex.
3.2. Whirlin increases TRPV1 expression
Having conﬁrmed the association of TRPV1 andWhirlin in cells and
neurons, we next investigated the inﬂuence of PDZ-scaffold protein in
TRPV1 expression. For this purpose, both proteins were co-transfected
into HEK293 cells and the expression level of TRPV1 was determined
by western immunoblot at 48 h. As shown in Fig. 2A, an increment in
Whirlin expression levels resulted in a dose-dependent increment of
TRPV1 expression up to ~2-fold at a TRPV1:Whirlin-myc cDNAs ratio
of 1:2 (Fig. 2B). This increment was also discernible at 24 h after trans-
fection (Supplementary information, Fig. S7A). A similar result was ob-
served when Whirlin-myc was transfected into a cell line that stably
expresses TRPV1 (Supplementary information, Fig. S7B), and into
primary nociceptor cultures (Fig. 2C). Overexpression of Whirlin in
nociceptors resulted in a signiﬁcant 1.4-fold increment of TRPV1 ex-
pression (Fig. 2D). Therefore, a notable effect of Whirlin expression is
to increase the total expression of TRPV1.
Subsequently, we evaluated if the higher levels of TRPV1 observed
when co-expressed with Whirlin also resulted in a higher delivery and
insertion into the plasma membrane. For this purpose, we evaluated
the receptor surface expression by biotinylation of membrane-
expressed proteins. Noteworthy, as shown in Fig. 2E and F,Whirlin pro-
duced a notable 2-fold increment in the localization of TRPV1 at the
plasma membrane that parallels the higher expression of the channel
induced by the cytoskeletal protein. This result was further substantiat-
ed in intact non-permeabilized cells using the TRPV1e antibody that rec-
ognizes an extracellular epitope (7). Sequential labeling with TRPV1e
and then against theWhirlin-myc protein (α-myc) clearly shows an in-
crease in membrane TRPV1 levels and cortical co-localization with
Whirlin (Fig. 2G). The higher TRPV1 levels at the plasma membrane
promoted by Whirling appear forming large receptor clusters, as evi-
denced by the enhanced clustered YFP-TRPV1 membrane labeling in
the presence of the PDZ scaffold protein (Fig. 2H). Therefore, these
results indicate that Whirlin is a PDZ-scaffold protein that increases
the membrane localization of TRPV1 in cells, and appears to promote
receptor clustering.
3.3. Overexpression of Whirlin marginally modulates TRPV1 channel
activity
Because Whirlin increases the expression of TRPV1, we next func-
tionally evaluated the effect of Whirlin on TRPV1 channel activity by
patch clamp and Ca2+ imaging. Surprisingly, Whirlin reduced, rather
than increased, the magnitude of the voltage-evoked TRPV1 ionic cur-
rents (Fig. 3A), as clearly evidenced by the decrease in the current den-
sity at high depolarizing potential (Fig. 3B). The kinetics of the ionic
currents was virtually identical in cells expressing only TRPV1 and
those co-expressing the channel and Whirlin (Fig. 3A). Analysis of theFig. 2.Whirlin expression enhances surface and total expression of TRPV1. (A, B) Representativ
entmolar ratios of TRPV1 andWhirlin-mycwhere a constant amount of TRPV1was applied alo
glycosylated TRPV1 forms. Actin was used as loading control for normalization. (C, D) Represen
withWhirlin-myc or YFP (as a control) cDNAs. (E, F) Representative immunoblot and quantiﬁc
of Whirlin-myc. Surface proteins were separated by biotinylation, immunopuriﬁed with avidin
and membrane expressed protein. (G) Immunolabeling of non-permeabilized intact control (
TRPV1e (green), an antibody that recognizes an extracellular epitope, and thereafter deterge
(H) YFP-TRPV1 expression in HEK293 cells in the absence (top) and presence of Whirlin (bott
The inset denotes a 2× zoom of the squared area. Scale bars 10 μm.conductance-to-voltage relationships revealed that the voltage depen-
dence of channel gating was slightly shifted to higher voltages in the
presence of Whirlin (Fig. 3C), indicating that the energetics of channel
gating was marginally increased (V0.5 = 96 ± 2 mV and V0.5 =
117± 3mV in the absence and presence ofWhirlin, respectively). Con-
versely, the PDZ-scaffold protein did not alter TRPV1 voltage sensitivity,
as evidenced by similar gating valence of the gating process (0.55 ±
0.03 and 0.58 ± 0.02 in the absence and presence of Whirlin,
respectively).
We also examined channel gating evoked by mild acidic extracellu-
lar pH and capsaicin. Akin to voltage-induced gating, Fig. 3D and F
shows a modest decrease in pH-gated TRPV1 currents at negative po-
tentials when Whirlin was co-expressed with the thermoTRP. In con-
trast, Whirlin expression did not signiﬁcantly affect the magnitude of
the capsaicin-activated ionic currents (Fig. 3E and G), nor capsaicin-
induced Ca2+ inﬂux (Fig. 3H–J). The apparently milder impact of
Whirlin on capsaicin responsesmay be due to its stronger activating po-
tency than voltage and pH, which are considered partial activators (4,
33). Taken together, these results imply that heterologous co-
expression of Whirlin with TRPV1 in HEK293 cells does not increase
TRPV1 channel activity, but rather marginally decreases the channel
functionality. This ﬁnding is consistent with the clustering of TRPV1 in-
duced by Whirlin (Fig. 2H), as TRPV1 clustering has been reported to
negatively modulate channel function (29).3.4. Silencing of Whirlin expression reduces TRPV1 cellular expression and
function
We next evaluated the functional consequences of abrogating
Whirlin expression using speciﬁc siRNAs. For this purpose, we ﬁrst
used F11 cells (34). Because F11 cells do not express Whirlin nor
TRPV1, we transfected them with both proteins. Twenty-four hours
later, these cells were re-transfected with one or a mix of the three
siRNAs designed against Whirlin, and the expression of both proteins
was evaluated by western immunoblot. As illustrated in Fig. 4A, the
three individual siRNAs signiﬁcantly reduced Whirlin protein levels.
This decrease was concomitant with a reduction in Whirlin mRNA
(data not shown). Notably, downregulation of Whirlin expression
with siRNAs resulted also in a signiﬁcant decrement of TRPV1 protein
levels in F11 cells co-transfected with TRPV1 and Whirlin (Fig. 4A).
This reduction is more evident for siRNA-1 and siRNA-2 than for
siRNA-3. As expected, transfection of these siRNAs against Whirlin sig-
niﬁcantly reduced TRPV1 levels and, concomitantly, the extent of
capsaicin-evoked Ca2+ responses in F11 cells co-expressing both pro-
teins (Supplemental information, Fig. S8). Since the three siRNAs dis-
play a similar functional effect, we selected the siRNA-2 for the next
experiments.
Immunocytochemical exploration of Whirlin and TRPV1 levels in
F11 cells in culture substantiated the effect of siRNA-2 on TRPV1 levels
obtained with western immunoblots. As illustrated in Fig. 4C, Whirlin
and TRPV1 co-localized in the same cells (top panel). Transfection
with a scrambled siRNA (sc-siRNA) did not affect the expression
ofWhirlin nor TRPV1 (Fig. 4B, bottom panel). Inmarked contrast, trans-
fection of siRNA-2 downregulated the expression of Whirlin and, con-
comitantly, virtually silenced the expression of TRPV1 (Fig. 4C, top
panel). This result suggests that inhibition of Whirlin synthesis bye immunoblot and quantiﬁcation of HEK293 extracts transiently cotransfectedwith differ-
ngwith increasingWhirlin-myc cDNA. TRPV1 appears as a double band depicting different
tative immunoblot and quantiﬁcation of neonatal rat DRG primary cultures electroporated
ation of surface expressed TRPV1 in HEK293 cells in the absence (YFP, control) or presence
and analyzed by immunoblot. Actin was used as loading control for normalization of total
TRPV1 + DsRed) or Whirlin-transfected (TRPV1 +Whirlin) cell membranes with anti-
nt-permeabilized for Whirlin staining (red). Cell nuclei were stained with DAPI (blue).
om). Data were expressed as mean ± SEM with N = 5. *p b 0.05 unpaired t-Student test.
122 M.G. Ciardo et al. / Biochimica et Biophysica Acta 1863 (2016) 115–127siRNA-2 results in a net degradation of both proteins, presumably
through the proteasome. To test this hypothesis, after transfecting the
siRNA into cells expressing both proteins, we incubated these cells
with the proteasomal inhibitor MG132 and examined the expression ofFig. 3. Effect of Whirlin on TRPV1 currents activated by voltage, acidic pH and capsaicin. (A) Re
100ms from Vh=−60mV in HEK293 cells transiently transfectedwith TRPV1+ YFP (control
+40mV and+180mV. Data are shown asmean± SEMwith n=23 cells for each condition. *p
and presence of Whirlin. Conductance values were ﬁtted to a normalized Boltzmann equation.
0.02, in the absence and presence of Whirlin, respectively. (D) Representative TRPV1 ionic cu
(E) The PDZ-scaffold protein decreases the magnitude of the acidic pH-activated TRPV1 ionic c
and presence of Whirlin. (G) Capsaicin responses were not affected by the presence of Whirl
n ≥ 22 for Whirlin expressing cells. *p b 0.05 unpaired t test. (H) Representative capsaicin-in
ﬁrst peak was evoked with 0.01 μM (Cap1), and the second with 100 μM (Cap2) capsaicin to
response. au denotes arbitrary units (J) Ratio between theﬁrst and the second capsaicin-evoked
No signiﬁcant differences were detected using a two-way ANOVA, followed by Bonferroni posWhirlin and TRPV1 by immunocytochemistry. Noteworthy, inhibition
of proteasome activity prevented the degradation of Whirlin and main-
tained the expression level of TRPV1 in cells transfected with the
siRNA-2 (Fig. 4C, bottom panel).presentative family of ionic currents evoked by step potentials from−120 to +220mV in
) or TRPV1+Whirlin. (B) Current densities (J, nA/pF) calculated frommaximal currents at
b 0.05, two-wayANOVA, Bonferroni post-test). (C) G–V relations for TRPV1 in the absence
V0.5 values were 97 ± 2 mV and 117 ± 3 mV, and zg values were 0.55 ± 0.03 and 0.58 ±
rrent evoked by an extracellular acidic pH of 6.0 in the absence and presence of Whirlin.
urrents. (F) Representative TRPV1 ionic current evoked by 1 μM capsaicin in the absence
in. For both conditions data are given as mean ± SEM, with n = 21 for control cells and
duced Ca2+ ﬂuxes in cells expressing TRPV1, and co-expressing TRPV1 and Whirlin. The
get a saturated response. (I) Average peak amplitude of the ﬁrst vanilloid-activated Ca2+
Ca2+ responses. Datawere expressed asmean± SEMwith n N 150 cells in each condition.
t-test.
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TRPV1 activity by Ca2+ microﬂuorography using Fluo4 as Ca2+ dye.
Fig.4D shows that transfection of F11 cells expressing Whirlin and
TRPV1 with siRNA-2 resulted in lower capsaicin response due to the de-
creased expression levels of TRPV1. siRNA-2 effect on TRPV1 expression
required the presence of Whirlin as it was ineffective in control F11 cells
thatwere not transfectedwith the PDZ-scaffolding protein, substantiating
the stabilizing effect ofWhirlin on TRPV1 expression. Furthermore, it was
sequence speciﬁc since the scrambled sc-siRNA did not affect TRPV1 ex-
pression levels nor activity (Fig. 4D). Notably, inhibition of proteasome ac-
tivity with MG132, which prevents the degradation of expressedWhirlin
and TRPV1 (Fig. 4C, bottom panel), attenuated TRPV1 downregulation in
cells transfected with siRNA2 (Fig. 4D). Collectively, these results suggest
that Whirlin stabilized the cellular and membrane expression of TRPV1.
Downregulation of the PDZ-scaffolding protein concomitantly reduced
the cellular and membrane levels of the thermoTRP channel.
We next sought to investigate the consequences of silencingWhirlin
in primary cultures of DRG neurons. For this purpose, primary cultures
of nociceptors were transfected with siRNA-2 and the expression of
Whirlin and TRPV1 was ﬁrst investigated by immunocytochemistry
(Fig. 5A). As siRNA control, we used sc-siRNA. Transfection of siRNA-2
in nociceptors in culture resulted in the virtual disappearance ofWhirlin
and the concomitant fading of TRPV1 levels. Akin to F11 cells, degrada-
tion of both proteins could be prevented by inhibition of the proteasomeFig. 4. Silencing of Whirlin expression decreases TRPV1 cellular levels. (A) Immunoblots showin
transiently expressed in F11 cells. Three different siRNAs (siRNA-1, siRNA-2 and si-RNA-3)were
and Whirlin (green) in control conditions and transfected with a scrambled siRNA (sc-siRNA).
Whirlin (green) transfected with siRNA-2 in the absence (top) and presence of MG132 (botto
absence of Whirlin and transfected with sc-siRNA or siRNA-2. Ca2+ responses were evoked w
response of TRPV1-expressing F11 untreated cells (Ø). siRNAs were transfected at 50 nM, a
mean ± SEM with N = 5. ***p b 0.001, two-way ANOVA, followed by Bonferroni post-test. Scawith MG132 (data not shown). To functionally investigate the effect of
siRNA-2, we transfected the neurons with a Cy3-siRNA-2:siRNA-2 mix-
ture or Cy3-sc-siRNA:sc-siRNA that allowed us to evaluate capsaicin-
induced Ca2+ inﬂux in transfected nociceptors (Fig. 5A). This was neces-
sary because of the high heterogeneity in capsaicin responses of primary
nociceptor cultures. Using this strategy, our data revealed a signiﬁcant
decrease in the percentage of capsaicin responsive neurons in cultures
transfected with siRNA-2, as compared with control and sc-siRNA-
transfected neurons. However, the magnitude of the capsaicin-evoked
Ca2+ responses in nociceptors was not signiﬁcantly affected by siRNA-
2 (data not shown), most likely because these responding neurons
may not co-express Whirlin and TRPV1. This result was further con-
ﬁrmed by patch clamp experiments in nociceptive neurons in culture
(Supplemental Fig. S9). Therefore, downregulation ofWhirlin expression
in a subpopulation of sensory neurons results in a decrease of TRPV1
expression, substantiating the stabilization of TRPV1 expression by the
cytoskeletal PDZ-scaffold protein.
3.5. Whirlin increased the stability of TRPV1 in cells
The effect of Whirlin on TRPV1 cellular stability was investigated by
monitoring the time course of the proteins cellular degradation upon
inhibition of protein synthesis with cycloheximide (Fig. 6A and B). In
the absence of Whirlin, TRPV1 is relatively stable, showing a slowg the effect of siRNAs against Whirlin on the levels of the PDZ-scaffold protein and TRPV1
used. (B) Immunocytochemical staining of F11 cells transiently co-expressing TRPV1 (red)
(C) Immunocytochemical staining of F11 cells transiently co-expressing TRPV1 (red) and
m). (D) Ca2+ microﬂuorographic assay in F11 cells expressing TRPV1 in the presence or
ith a 100 μM capsaicin. Area under the curve (AUC) was calculated and normalized to the
nd proteasomal inhibition was carried out with 2 μM MG132. Data were expressed as
le bar 10 μm.
Fig. 5. Silencing of Whirlin expression reduces TRPV1 neuronal levels and the number of capsaicin responding nociceptors. (A) Immunocytochemical TRPV1 (red) and Whirlin (green)
staining of rat neonatal DRGs transfected with 50 nM siRNA-2 or sc-siRNA. Non-transfected cells were used as control. (B) Rat neonatal DRG cultures were transfectedwith a Cy3-labeled
siRNA-2::siRNA-2 (1:10) to visualize transfected neurons. Trypan blue staining revealed an ~70% cell viability at 48 h post-transfection. (C) Percentage of Capsaicin responding neurons
determined by Ca2+ imaging. Whirlin silencing was reduced the percentage of capsaicin sensitive neurons by ~40%. Capsaicin concentration usedwas 0.5 μM. Data are shown asmean±
SEM, with n ≥ 165 neurons in three different experiments. *p b 0.05, one way ANOVA, followed by Bonferroni post-test. Scale bar 10 μm.
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tional arrest. Unexpectedly, in the presence of Whirlin the receptor ex-
hibited signiﬁcantly faster elimination kinetics and higher degradation,
as ≥80% of TRPV1 faded away after 24 h (Fig. 6B). Noteworthy, the faster
and more extensive TRPV1 degradation in the presence of Whirlin
closely matches the kinetics ofWhirlin elimination (Fig. 6B), suggesting
a causal relation in the degradation of both proteins. Indeed, this result
suggests that in the presence of Whirlin the elimination of the
thermoTRP is driven by the PDZ-scaffold protein, and probably depicts
the degradation of the protein complex. This ﬁnding is in agreement
with the observed degradation of TRPV1 induced by silencing ofWhirlin
expression with siRNAs.
To further examine the effect of Whirlin on the cellular stability of
TRPV1, we compared the expression levels of TRPV1 before and after
inhibiting lysosomal and proteasomal degradation in the absence and
presence of Whirlin. As illustrated in Fig. 6C and D, inhibition of lyso-
somal activity with Leupeptin (L) did not affect the level of TRPV1 inde-
pendently of the presence of Whirlin. In marked contrast, inhibition of
the proteasome with Epoxomicin (E) signiﬁcantly augmented the ex-
pression level of TRPV1 in the absence of Whirlin (Fig. 6D), implying
that, under these conditions, TRPV1 turnover ismediated via theprotea-
some. In the presence of Whirlin, however, the proteasomal inhibitor
did not affect the level of channel expression (Fig. 6D), suggesting a
lower turnover of the receptor in the presence of the PDZ-scaffold pro-
tein. Taken together, these results strongly suggest thatWhirlin reduced
the amount of channel protein being degraded, implying a stabilization
of TRPV1 expression by the PDZ-scaffold protein.
We have previously reported that degradation of TRPV1 can be
evoked by long exposure of the receptor to capsaicin, a process that tar-
gets the thermoTRP to lysosomal degradation (35). Thus, we next hy-
pothesized that Whirlin-mediated stabilization of TRPV1 cellular
expressionmay also reduce the extension of vanilloid-induced receptor
internalization and degradation. Accordingly, we next investigated the
effect of Whirlin on agonist-evoked receptor elimination and evaluated
the levels of TRPV1 upon prolonged exposure to capsaicin in the ab-
sence and presence of Whirlin. As depicted in Fig. 6E, in the absence ofWhirlin, 20 min incubation with capsaicin of cells expressing TRPV1
produced a 60% decrease in the receptor expression. In contrast, in the
presence of Whirlin, this reduction was signiﬁcantly lower (Fig. 6F),
consistent with a higher cellular stability of TRPV1 in the presence of
the PDZ-scaffold protein that can even partially reduce vanilloid-
induced lysosomal degradation of TRPV1. Collectively, all these results
indicate that the main effect of Whirlin–TRPV1 interaction is to aug-
ment the stability of TRPV1, most likely by increasing its membrane
stability.
4. Discussion
The activity of ion channels, including thermoTRPs, depends on the
interaction of these membrane proteins with a plethora of partners
that ensure their proper cellular activity. Analysis of the TRPV1
channelosome or signalplex has identiﬁed thus far protein partners
mainly involved in receptor trafﬁcking, delivery and clustering into
the plasmamembrane, as well as proteins that modulate its channel ac-
tivity (16,29,36). Furthermore, interferingwith receptor membrane de-
livery has resulted in a useful pharmacological approach to understand
the contribution of TRPV1 pathological recruitment to pain transduction
(7), and a therapeutic strategy to reduce pain signaling (37). Therefore,
unveiling the components of the TRPV1 signalplex is important for un-
derstanding the intricacies of the receptor pathophysiological regula-
tion. Indeed, identiﬁcation of these protein complexes may provide
new therapeutic targets for drug intervention.
By using a yeast two-hybrid approach, we have identiﬁedWhirlin, a
PDZ-scaffold protein, as an interacting partner of TRPV1. In humans,
Whirlin is encoded by the gene Deafness Autosomal Recessive 31,
which is pivotal for retinal photoreceptor and vestibular and cochlear
hair cells function (38,39). Indeed, mutations in this gene have been as-
sociated with autosomal recessive non-syndromic deafness and the
Usher Syndrome (22,23). Additionally, this protein has been also impli-
cated inmechanotransduction, a role recently substantiated by virtue of
its location in peripheral proprioceptors where it facilitates afferent ﬁr-
ing in response tomuscle stretch (24).Whirlinwas initially identiﬁed as
Fig. 6. Effect ofWhirlin on TRPV1 cellular andmembrane levels. (A) Kinetics of TRPV1 andWhirlin-myc expression after arresting protein translationwith 300 μg/ml cycloheximide (CHX)
analyzed by western immunoblot of both proteins. (B) Quantitation of TRPV1 andWhirlin-myc protein normalized levels upon incubationwith CHX. Quantitation was performed by dig-
itizing the immunoblots. (C) Immunoblots showing the effect of Leupeptin (L) and Epoxomicin (E) on TRPV1 expression in the absence and presence ofWhirlin-myc. (D) Quantitation of
TRPV1 levels in the immunoblots depicted in panel C. Control depicts HEK293 cells co-transfectedwith TRPV1 and YFP.Whirlin-myc depicts HEK293 cells co-transfectedwith TRPV1 and
Whirlin-myc. Cells were treatedwith 100 μMLeupeptin or 1 μMEpoxomicin, or their respective vehicles water (Veh-L) and DMSO (Veh-E) for 12 h. (E, F) Representative immunoblots of
the effect of 20min capsaicin exposure on TRPV1membrane levels in the absence andpresence ofWhirlin.HEK293 cells treatedwith 10 μMcapsaicin or vehicle (DMSO) for 20min at 37 °C
and, thereafter, biotinylated, avidin afﬁnity puriﬁed and analyzed by western immunoblot. Data are given as mean ± SEM with N = 5. *p b 0.05; **p b 0.01, unpaired t-Student test.
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family that plays important roles in the molecular organization of syn-
aptic proteins in the central nervous system (21). Thus, Whirlin, as
other PDZ-scaffold proteins, may be essential for the assembly and sta-
bilization of protein networks in synapses (40), as well as in peripheral
sensory endings of proprioceptive neurons (24). Our ﬁnding that
Whirlin interacts with TPRV1 in peripheral nociceptors further substan-
tiates a signiﬁcant role of this protein in sensory transduction. Indeed,
we found thatWhirlin isoforms (long and short) form a stable complexwith the N-terminal domain of TRPV1. Notably, this complex appears
mediated by non-canonical PDZ interactions (41), as TRPV1 does not
display a PDZ ligand in the N-terminus domain. Thus, the assembly of
both proteins seems mainly due to the binding of the ankyrin and PDZ
domains.
The most salient contribution of our study is that Whirlin associates
with TRPV1 and increases the expression level and the stability of
TRPV1. In transfected cell lines, the heterologous co-expression of
Whirlin with TRPV1 augmented the expression of the receptor, as well
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when the PDZ-scaffold protein was overexpressed in primary cultures
of rat sensory neurons. Intriguingly, however, the larger TRPV1 expres-
sion in the presence of Whirlin did not result in a concomitant increase
in channel activity suggesting that the PDZ-scaffold protein may exert a
direct or indirect inhibitory action on TRPV1 channel activity. Although
it is normally expected that an increase in protein expression leads to
higher activity, it must be also noticed that increasing the membrane
expression of a channel protein may induce its clustering, which could
be detrimental for channel activity as clustered channels may exhibit
impaired gating. In support of this tenet, we previously demonstrated
that GABARAP-induced clustering of TRPV1 in the cell membrane re-
sulted in a decrease of channel activity, even though GABARAP notably
augmented the total and membrane expressed TRPV1 (29). Here, we
noticed that Whirlin increased TRPV1 clustering in the cell membrane,
thus providing an explanation for the apparent lower channel activity
of receptor in the presence of the PDZ scaffold protein. A recent study
on the spatiotemporal organization of TRPV1 in live cell membranes
shows the existence of three dynamic channel populations, one of
them bound to microtubules (42). This cytoskeletal population appears
as large clusters (860 nm) of slow mobility. It is tempting to speculate
that Whirlin, as well as GABARAP (29), may favor the formation of
this clustered receptor population. In support of this tenet, Whirlin re-
duced capsaicin-induced TRPV1 internalization, a process that has
been associated to the channel subpopulation bound to caveolin-1 (29).
A more discernible effect on TRPV1 function was obtained when
Whirlin expression was reduced using a speciﬁc siRNA. In recombinant
F11 cells co-expressing Whirlin and TRPV1, knockdown of Whirlin ex-
pression notably reduced the expression level of TRPV1 and signiﬁcantly
decreased capsaicin-activated responses. Inhibiting the proteasome activ-
ity, a strategy that prevented the degradation of bothWhirlin and TRPV1,
preserved TRPV1 expression and vanilloid responses in these cells. Fur-
thermore, treatment of primary cultures of nociceptors with Whirlin
siRNA, also decreased the expression of TRPV1 and decreased the per-
centage of neurons responding to capsaicin. Taken together, these results
indicate thatWhirlin complexeswith TRPV1 and stabilizes the expression
of the vanilloid receptor. Silencing the expression of the PDZ-scaffold
protein then results in a lower stability of TRPV1 that is eliminated con-
comitantly with Whirlin through proteasomal degradation.
It is intriguing that TRPV1 cellular stabilization is only observed
when Whirlin is co-expressed with TRPV1, as TRPV1 is quite stable
in cells in the absence of Whirlin. Furthermore, elimination of Whirlin
in nociceptors in culture only affected the percentage of neurons
responding to capsaicin but not the magnitude of the vanilloid-
induced responses. These observations suggest that what is likely de-
graded in cells expressing both proteins is theWhirlin–TRPV1 complex.
In support of this tenet, TRPV1 degradation upon treating the cells with
cycloheximide follows an elimination kinetics virtually identical to that
ofWhirlin in cells where both proteins are co-expressed, and it is signif-
icantly faster and more extensive than that where only TRPV1 is
expressed. This result implies that, in the presence ofWhirlin, the stabil-
ity of TRPV1 is primarily determined by formation of the Whirlin–
TRPV1 complex. Taken together, Whirlin appears to form a stable com-
plex with TRPV1 that increases the cellular stability of the thermoTRP.
Additional support for this notion is provided by the lower internaliza-
tion and degradation of TRPV1 induced by prolonged exposure of the
receptor to capsaicin in the presence of Whirlin.
Mutations in the humanWhirlin gene are responsible for autosomal
recessive deafness DFNB31 and in cases of Usher syndrome type 2D in
humans, and for the deafness phenotype in the Whirler mouse (20,22,
23). Genetically, the mutation in the Whirler mice consists of a 592 bp
deletion that leads to a truncation of the long isoform before the third
PDZ and encompasses the ﬁrst methionine of the short isoform (20).
A question that arises is whether the Whirler mouse displays
nociception abnormalities due to destabilization of the Whirlin–TRPV1
complex because of the truncation of Whirlin. Notably, we did notobserve any signiﬁcant nociceptive impairment inWhirlermice as com-
pared with wild type littermates (Supplementary Table S1). Similarly,
we did not detect any noticeable nociceptive deﬁcit in a Whirlin trans-
genic mouse (Whirlinneo/neo) that does not express the long isoform of
the PDZ protein (Supplementary Table S2) (26). These results are con-
sistent with our observation that TRPV1 is able also to interact with
the PDZ1/2 and PDZ3 domains, suggesting an interaction with the
long and short isoforms of the PDZ-scaffold protein. Indeed, the whirler
andWhirlinneo/neo mice exhibit a similar distribution of TRPV1 in senso-
ry ﬁbers (Table 1 and Supplementary Figs. S10–S15). Thus, the lack of
nociceptive impact observed in Whirler and Whirlinneo/neo mice may
be due to the complexation and stabilization of TRPV1 with the short
Whirlin isoforms expressed by nociceptors of these animals. Notably,
an alternative Whirlin transgenic mouse, produced using a genome-
wide knockout generation approach and characterized using systematic
phenotyping, exhibited an increased thermal nociceptive threshold in
the hot plate test (43), consistent with a defect in the activity of
TRPV1 receptors in the peripheral terminals of these animals. Neverthe-
less, additional nociceptive characterization of these transgenic mice
appears necessary to unveil the pathophysiological role of Whirlin–
TRPV1 complex in nociceptive and pain signaling.
In conclusion, we have described that TRPV1 interacts withWhirlin,
a cytoskeletal PDZ-scaffold protein, in nociceptors. The main functional
role of the TRPV1–Whirlin complex is to stabilize the total and
membrane expression of TRPV1,most likely in the peripheral terminals.
Because the interaction ofWhirlin with TRPV1 involves the ankyrin do-
mains, it is plausible that the PDZ-scaffold protein also associates with
other ankyrin-containing TRP channels, thus providing a mechanism
to assemble and stabilize these channels in the peripheral nociceptive
and propioceptive terminals. It would be also interesting to know if
other TRP channels also interact with Whirlin, and if they contribute
to deﬁne the phenotype characteristic ofWhirlinmutants, namely deaf-
ness and the Usher syndrome. Although additional experimental sup-
port is needed to better understand the role of Whirlin assembling
TRPV1 channels and nociceptor peripheral terminals, our data suggest
that disruption of its interaction with TRPV1 may provide a novel phar-
macological intervention to attenuate TRPV1 dysfunction in peripheral
painful syndromes. Because full pharmacological abrogation of TRPV1
channel activity has not delivered yet a clinically useful approach due
to unwanted side effects, exploration of alternative therapeutic ap-
proaches directed to modulate TRPV1 expression levels may lead to
compounds with higher therapeutic index.
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